» Articles » PMID: 18053459

Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Rural Tertiary Care Practice: a Retrospective Analysis

Overview
Journal Mayo Clin Proc
Specialty General Medicine
Date 2007 Dec 7
PMID 18053459
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To review the clinical and laboratory features of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) in a rural tertiary care rheumatology practice, describe treatments and outcomes, and compare our results to previous reports in the literature.

Patients And Methods: We performed a retrospective chart review of all patients diagnosed as having RS3PE who were seen in the Department of Rheumatology at Geisinger Medical Center, Danville, PA, from January 1, 1992, to December 31, 2005.

Results: We identified 12 men and 2 women, all of whom were white. Mean +/- SD age was 74.0 +/- 6.6 years; mean +/- SD erythrocyte sedimentation rate was 35.9 +/- 21.1 mm/h at presentation. Onset of illness was sudden in 9 patients and insidious in 5. All patients were initially treated with prednisone (15-20 mg/d). Although the response in all was excellent, 9 patients received disease-modifying antirheumatic drugs, either because of ongoing disease activity or in an effort to decrease the use of corticosteroids. Hydroxychloroquine was used alone in 7 patients. At the mean +/- SD time of last follow-up (31.4 +/- 23.1 months), 5 patients continued to receive therapy. Complications of treatment included worsening of preexisting hypertension in 3 patients, gastritis in 2, and exacerbation of preexisting diabetes mellitus in 1. Carpal tunnel syndrome occurred in 6 patients. Duration of therapy ranged from 5 to 120 months (mean, 29 months). Three patients developed malignancies, ie, non-Hodgkin lymphoma, transitional cell carcinoma of the bladder, and prostate carcinoma.

Conclusion: Our population of patients with RS3PE is similar to those documented in previous reports: elderly, predominantly male, and responsive to corticosteroids. However, our series is clinically differentiated by a greater use of adjunctive disease-modifying antirheumatic drugs (primarily hydroxychloroquine). Confirming previous reports, we also observed a possible association between RS3PE and malignancy.

Citing Articles

[Remitting seronegative symetrical synovitis with pitting edema. One case report].

Pimentel-Leon R, Garcia-Chavez M, Chavez-Sanchez I Rev Med Inst Mex Seguro Soc. 2023; 61(3):363-369.

PMID: 37216683 PMC: 10437230.


Evaluation of clinical efficacy of tumor necrosis factor‑α inhibitors in treatment of distal extremity swelling with pitting edema in psoriatic arthritis of inadequate response to conventional therapy: A 10‑year retrospective study.

Zhao C, Liu B, Yao Y, Yang K, Zang B, Liu B Exp Ther Med. 2023; 25(6):263.

PMID: 37206568 PMC: 10189727. DOI: 10.3892/etm.2023.11962.


Remitting seronegative symmetrical synovitis with pitting edema: a case report.

Tanaka Y, Kohchi K, Kitamoto K J Med Case Rep. 2022; 16(1):125.

PMID: 35331322 PMC: 8944117. DOI: 10.1186/s13256-022-03310-0.


Remitting seronegative symmetric synovitis with pitting edema (RS3PE) with painful erythematous nodules.

Laidler N, Delaney T BMJ Case Rep. 2020; 13(4).

PMID: 32327460 PMC: 7202784. DOI: 10.1136/bcr-2019-234197.


Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report.

Ngo L, Miller E, Valen P, Gertner E J Med Case Rep. 2018; 12(1):48.

PMID: 29478412 PMC: 6389137. DOI: 10.1186/s13256-018-1579-1.